Study to Evaluate the Efficacy and Safety of ATNC-MDD V1(TMS With Cognitive Training) in Mild Alzheimer's Dementia

Prior treatment

• Patients who have been unconscious due to brain surgery or concussion, or who have signs or symptoms of cranial pressure elevation on neurologic examination.
• Patients with metal implants in the head, (i.e. cochlear implants, implanted brain stimulators and neurostimulators, aneurysm clips) with the exception of metal implants.
• Implanted medication pumps.
• Patients who are currently taking medications that lower the convulsive seizure threshold.
• Patients who participated in other clinical trials 3 months before participating in this clinical trial.
  • ※ Subjects who participate in non-interventional studies (such as observational studies) that do not affect the subject's disease or symptoms may be enrolled in the study.
• Patients who need to take medications suggested in concomitantly contraindicated drugs.

Other illness

• Patients with central nervous system (CNS) disorders that may affect cognitive function (such as cerebrovascular diseases including vascular dementia, subdural hematoma, normal pressure hydrocephalus, brain tumors, CNS infections like HIV or syphilis, head trauma, Huntington's disease, Parkinson's disease, etc.) where cognitive decline may be explained by other causes, or in whom dementia types other than Alzheimer's disease are suspected.
• History of Epileptic Seizures or Epilepsy.
• Patients with a history of drug abuse, including alcohol, in the past 5 years from the time of screening.
• Patients with schizophrenia, schizoaffective disorder, bipolar disorder, current major depressive episode, psychosis, panic, post-traumatic stress, severe anxiety, mental retardation, DSM-V disorder.
• Patients with abnormal vitamin B12, folic acid deficiency, or thyroid stimulating hormone (TSH) test results that were considered by the investigator to affect or are caused by the severity of dementia.
• Cardiac pacemakers.
• Significant heart disease.
• Patients with severe renal or hepatic impairment※, referring to conditions that significantly affect daily living (e.g., stage 4 chronic kidney disease), with the assessment based on the investigator's judgment.
• Patients with a history of TMS treatment within the last 2 years before participating in this clinical trial.
• Patients with a history of malignant tumors within the last 5 years.
  • \- Participation is possible if more than 5 years have elapsed without recurrence after the decision to be cured (The point of complete removal of the tumor through surgery or the end of chemotherapy, etc.).

Other

• Intracardiac lines.
• Contraindication for performing MRI scanning.
• Contraindication for performing amyloid PET-CT scanning.
• Patients who do not consent to TMS treatment and participation in this clinical trial.
• Patients judged by the investigator to be unsuitable for participation in clinical trials for other reasons.
  • ※ If the test subject is unable to visit according to the research plan due to unavoidable personal circumstances during the screening period, it will be treated as a screening dropout, and the patient can participate in the study after re-agreeing according to the future schedule.

• Patients who started drug treatment with an acetylcholinesterase inhibitor at least 2 months before participating in the clinical trial and can participate in the clinical trial without changing the dose during the trial period.
• Male or female age 60-85 years.
• Patients diagnosed with mild stage of Alzheimer's Disease, according to the NIA-AA (2011) diagnosis.
• A patient whose dementia was confirmed to be due to Alzheimer's disease by amyloid PET-CT.
• MMSE score 21 to 26.
• CDR 1 or GDS 3.
  • ※ For subjects who are excluded from screening based on criteria 5 or 6, if the investigator judges that the subject is likely to be eligible, one repeat screening may be performed.
• A patient who is deemed physically eligible for the clinical trial based on medical records and physical examination.
• A patient who is unable to provide voluntary informed consent for the clinical trial due to impaired decision-making capacity, for whom a legally authorized representative provides consent for participation, and who can attend follow-up visits with a caregiver.
• Patients who agreed to participate in all 24-week clinical trials.
• Patients with normal ability to see and hear letters.
• Patients who speak Korean as their mother tongue